Quick Answer
Trevi Therapeutics, Inc. reported Stockholders Equity of $183.24 million for the year ending 2025.
- Trevi Therapeutics, Inc. showed an increase of +83.9% in Stockholders Equity from 2024 to 2025.
- This data is from Trevi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$89.46 million | Q2 2018: -$95.34 million | Q3 2018: -$102.33 million | Q1 2019: -$115.48 million | Q2 2019: $67.70 million | Q3 2019: $60.71 million | Q1 2020: $46.80 million | Q2 2020: $40.04 million | Q3 2020: $35.62 million | Q1 2021: $23.69 million | Q2 2021: $17.74 million | Q3 2021: $11.38 million | Q1 2022: $10.46 million | Q2 2022: $60.52 million | Q3 2022: $109.90 million | Q1 2023: $101.73 million | Q2 2023: $95.07 million | Q3 2023: $89.61 million | Q1 2024: $72.33 million | Q2 2024: $66.17 million | Q3 2024: $58.97 million | Q1 2025: $99.46 million | Q2 2025: $198.49 million | Q3 2025: $189.79 million.
- Over the full 9 years of available data (2017 to 2025), Trevi Therapeutics, Inc.'s Stockholders Equity has grown by 317.0%.
- Historical annual values: Fiscal year 2025: $183.24 million | Fiscal year 2024: $99.64 million | Fiscal year 2023: $82.55 million | Fiscal year 2022: $107.46 million | Fiscal year 2021: $17.08 million | Fiscal year 2020: $27.28 million | Fiscal year 2019: $54.55 million | Fiscal year 2018: -$109.49 million | Fiscal year 2017: -$84.43 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: